[1] |
CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili.
One case of severe liver injury caused by Tianma Shouwu tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
|
[2] |
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping.
The role of MRPs transporters in drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
|
[3] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[4] |
BUCHANAN James.
Assessment of drug-induced liver injury via nR modified Hy’s law and PALT
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.
|
[5] |
LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli.
Adverse reactions in patients with COVID-19 after using tocilizumab
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
|
[6] |
CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao.
Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
|
[7] |
YU Lecheng, HAO Kunyan, FAN Ye.
Clinical diagnosis of Chinese-herbal-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 481-488.
|
[8] |
ZHU Chunwu, YU Xuejun, SUN Xin, LIU Chenghai.
Overview of hepatotoxicity of Xianling Gubao capsules
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 496-499.
|
[9] |
LUO Qiong, LI Meng, LI Guangyao, HE Yanchun, ZHOU Zushan, SUN Xin, LIU Chenghai.
Chinese medical evidence and characteristics of combined medication in 635 cases of rheumatoid arthritis patients with liver injury caused by the application of Tripterygium wilfordii preparations
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 500-504.
|
[10] |
LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai.
Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
|
[11] |
LIU Baosheng, WANG Guanjie, WANG Zhenhua, LIU Lihong, ZHU Yan, ZHOU Xiuli.
One case of acute liver injury caused by tripterygium glycosides tablets
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 511-513.
|
[12] |
XU Shuai, CHEN Xun, BIAN Haoyu, ZHAO Yuqing, ZHANG Liping.
Research hotspots and trends of herb-induced liver injury based on CiteSpace knowledge maps
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 560-567.
|
[13] |
YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan.
Comparative study on data set of drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573.
|
[14] |
CHEN Chao, ZHU Lan, LIU Lihong, HAN Jiayin, ZHU Yan.
Characteristics of Psoralea corylifolia induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 449-453.
|
[15] |
WANG Guanjie, DU Shifang, LIU Baosheng, HAN Jiayan, WANG Zhenhua, LU Changfei.
107 cases of liver injury caused by traditional Chinese medicines
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 331-333.
|